Want to see FOFA full AI Analyst Report?
Top Page
Family Office of America
(OTC:FOFA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.93
▼(-7.40% Downside)
Action:Reiterated
Date:08/08/26
The score is primarily constrained by ongoing unprofitability and a historically volatile financial profile despite a notable TTM revenue rebound and reduced cash burn. Technical signals are mixed with weak momentum, and valuation remains unfavorable due to losses and no dividend support.
Positive Factors
Top-line Recovery
A meaningful TTM revenue rebound (~$1.0M) signals renewed product or market traction rather than a one-off spike. If sustained, rising top-line creates room to leverage fixed costs, improve operating leverage and accelerate the path toward durable profitability over the next several quarters.
Negative Factors
Ongoing Losses
Sustained negative net margins (-11% TTM) mean the business still consumes capital to operate. Persistent losses reduce retained equity, limit internal reinvestment capacity, and create a structural need for external funding, which can constrain strategic choices and slow long-term value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Top-line Recovery
A meaningful TTM revenue rebound (~$1.0M) signals renewed product or market traction rather than a one-off spike. If sustained, rising top-line creates room to leverage fixed costs, improve operating leverage and accelerate the path toward durable profitability over the next several quarters.
Read all positive factors
Family Office of America (FOFA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.62M
Dividend YieldN/A
Average Volume (3M)28.00
Price to Earnings (P/E)―
Beta (1Y)-0.40
Revenue GrowthN/A
EPS Growth50.47%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,826,004
10 Day Avg. Volume55
30 Day Avg. Volume28
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)11.10
Price to Sales (P/S)33.25
P/FCF Ratio-8.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Family Office of America Business Overview & Revenue Model
Company Description
Family Office of America, Inc. specializes in delivering a broad spectrum of services designed for family offices. Their expertise spans accounting and tax strategy, comprehensive wealth and asset administration, meticulous estate planning, robust...
How the Company Makes Money
null...
Family Office of America Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
57
Neutral
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.54M | 221.76K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.48M | 221.76K | 0.00 | -17.25K | 0.00 | 0.00 |
| EBITDA | -113.31K | -449.15K | -95.01K | -223.00K | -560.90K | -1.14M |
| Net Income | -155.56K | -492.75K | -100.48K | -805.00K | -921.00K | -1.73M |
Balance Sheet | ||||||
| Total Assets | 2.65M | 1.54M | 20.58K | 2.43K | 295.46K | 800.06K |
| Cash, Cash Equivalents and Short-Term Investments | 636.89K | 155.80K | 13.59K | 2.43K | 69.86K | 528.28K |
| Total Debt | 312.57K | 300.00K | 0.00 | 9.10K | 31.19K | 0.00 |
| Total Liabilities | 447.11K | 878.53K | 44.02K | 525.39K | 71.51K | 29.65K |
| Stockholders Equity | 997.20K | 664.51K | -23.44K | -522.96K | 223.95K | 770.41K |
Cash Flow | ||||||
| Free Cash Flow | 195.50K | -822.79K | -89.37K | -76.53K | -558.43K | -794.63K |
| Operating Cash Flow | 195.50K | -262.19K | -89.37K | -76.53K | -558.43K | -792.84K |
| Investing Cash Flow | -598.88K | -560.60K | 0.00 | 0.00 | 0.00 | -1.79K |
| Financing Cash Flow | 455.00K | 965.00K | 100.53K | 9.10K | 100.00K | 1.25M |
Family Office of America Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $24.58M | -0.56 | -264.79% | ― | ― | 77.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $27.62M | -369.57 | -60.28% | ― | ― | 50.47% | |
42 Neutral | $8.71M | -0.30 | -246.04% | ― | ― | 66.94% | |
42 Neutral | $13.20M | >-0.01 | -123.29% | ― | ― | ― |
* Healthcare Sector Average
FOFA
Family Office of America
0.95
0.67
238.08%
SNGX
Soligenix
0.38
-4.58
-92.32%
CLRB
Cellectar Biosciences
2.56
-2.14
-45.53%
AKTX
Akari Therapeutics
7.52
-32.48
-81.20%
MGRX
Mangoceuticals, Inc.
0.53
-1.04
-66.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.